In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate

Document Type : Original Article


1 Pharmaceutical Biomaterials Department, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran

2 Department of Molecular Medicine, Pasture Institute of Iran, Tehran, Iran

3 Department of Chemistry, University of Zanjan, Zanjan, Iran

4 Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, Iran

5 Department of Pharmaceutical Biotechnology, Zanjan University of Medical Sciences, Zanjan, Iran


Objective(s): In this study, Boltorn® H40-PEG-MTX-anti-VEGFR2 nanobody was fabricated in which nanobody was selected for blocking the receptor, H40 as a nanocarrier for delivery of methotrexate (MTX) to the tumor cells, and polyethylene glycol (PEG) moieties for improving the blood circulation time and safety. 
Materials and Methods: The synthesis process of the nanosystem has been characterized by different analytical methods. 
Results: The prepared nanoplatform exhibited high drug loading capacity, excellent colloidal stability, and an average particle size of around 105 nm. MTX was successfully conjugated through ester bonds and its release profile clearly showed that the ester bond is in favor of releasing the drug in acidic pH (5.5). The cytotoxicity of the developed nanoplatform exhibited great anti-cancer activity against MCF7 and KDR293 (cells with overexpressed anti-VEGFR2 NB receptors) cell lines while no deleterious toxicity was observed for nanocarrier against HEK293 normal cells.  Furthermore, both hemolysis and LD50 assay results confirmed the hemocompatibility and biocompatibility of the developed nanoplatform. 
Conclusion: The most striking result to derive from the data is that the designed nanoplatform could potentially inhibit cell migration and invasion and the anti-angiogenesis properties of the developed nanoplatform may serve as a promising nanosystem to suppress the formation of blood vessels around tumor cells and consequently inhibit tumor progression.


1. Hong S, Tan M, Wang S, Luo S, Chen Y, Zhang L. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. J Cancer Res Clin Oncol 2015; 141: 909-921.
2. Gupta MK, Qin R-Y. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 2003; 9: 1144-1155.
3. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991; 51: 6180-6184.
4. Yadav L, Puri N, Rastogi V, Satpute P, Sharma V. Tumour angiogenesis and angiogenic inhibitors: a review. J Clin Diagn Res 2015; 9: XE01.
5. Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mihu C, Istrate M, et al. Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis. Rom J Morphol Embryol 2018; 59: 455-467.
6. Saberi-Karimian M, Katsiki N, Caraglia M, Boccellino M, Majeed M, Sahebkar A. Vascular endothelial growth factor: An important molecular target of curcumin. Crit Rev Food Sci Nutr  2019; 59: 299-312.
7. Abe I, Islam F, Lo CY, Liew V, Pillai S, Lam AK. VEGF-A/VEGF-B/VEGF-C expressions in non-hereditary, non-metastatic phaeochromocytoma. Histol Histopathol 2021; 36: 645-652.
8. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277-2285.
9. Neves KB, Montezano AC, Lang NN, Touyz RM. Vascular toxicity associated with anti-angiogenic drugs. Clin Sci 2020; 134: 2503-2520.
10. Chen WH, Luo GF, Zhang XZ. Recent advances in subcellular targeted cancer therapy based on functional materials. Adv Mater 2019; 31: 1802725.
11. Rashidzadeh H, Rezaei SJT, Zamani S, Sarijloo E, Ramazani A. pH-sensitive curcumin conjugated micelles for tumor triggered drug delivery.J Biomater Scie Polym ED 2021; 32: 320-336.
12. Rezaei SJT, Sarijloo E, Rashidzadeh H, Zamani S, Ramazani A, Hesami A, et al. pH-triggered prodrug micelles for cisplatin delivery: preparation and in vitro/vivo evaluation. React Funct Polym 2020; 146: 104399.
13. Peterson GM, Thomas J, Yee KC, Kosari S, Naunton M, Olesen IH. Monoclonal antibody therapy in cancer: When two is better (and considerably more expensive) than one. J Clin Pharm Ther 2018; 43: 925-930.
14. Nagano T, Tachihara M, Nishimura Y. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells 2018; 7: 212-227.
15. Kim JH, Kim JE, Hong YS, Kim SY, Kim K-p, Choi KE, et al. Increased incidence of chemoport-related thrombosis in patients with colorectal cancer receiving bevacizumab: A single-institutional experience. Chin J Cancer Res 2018; 30: 460-467.
16. Tu Z, Huang X, Fu J, Hu N, Zheng W, Li Y, et al. Landscape of variable domain of heavy‐chain‐only antibody repertoire from alpaca. Immunology 2020; 161: 53-65.
17. Brooks CL, Rossotti MA, Henry KA. Immunological functions and evolutionary emergence of heavy-chain antibodies. Trends Immunol 2018; 39: 956-960.
18. Khodabakhsh F, Behdani M, Rami A, Kazemi-Lomedasht F. Single-domain antibodies or nanobodies: a class of next-generation antibodies. Int J Immunol 2018; 37: 316-322.
19. Kolkman JA, Law DA. Nanobodies–from llamas to therapeutic proteins. Drug Discov Today Technol 2010; 7: e139-e146.
20. Wang L, Zhang G, Qin L, Ye H, Wang Y, Long B, et al. Anti-EGFR binding nanobody delivery system to improve the diagnosis and treatment of solid tumours. Recent Pat Anti-Cancer Drug Discov 2020; 15: 200-211.
21. Roovers RC, Vosjan MJ, Laeremans T, el Khoulati R, de Bruin RC, Ferguson KM, et al. A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer 2011; 129: 2013-2024.
22. Oliveira S, Schiffelers RM, van der Veeken J, van der Meel R, Vongpromek R, en Henegouwen PMvB, et al. Down-regulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release 2010; 145: 165-175.
23. Sayed-Tabatabaei L, Varshosaz J, Javanmard SH, Soghrati S. Camouflaged liposomes by 11A4-nanobody for co-delivery of cisplatin and nitroxoline in breast cancer tumors: An in vitro/in vivo study. J Drug Deliv Sci Technol 2022; 71:103273.
24. Akhter MH, Rizwanullah M, Ahmad J, Ahsan MJ, Mujtaba MA, Amin S. Nanocarriers in advanced drug targeting: setting novel paradigm in cancer therapeutics. Artif Cells Nanomed Biotechnol  2018; 46: 873-884.
25. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun 2018; 9: 1-12.
26. Zhou Q, Zhang L, Yang T, Wu H. Stimuli-responsive polymeric micelles for drug delivery and cancer therapy. Int J Nanomed 2018; 13: 2921-2942.
27. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010; 75: 1-18.
28. Rashidzadeh H, Tabatabaei Rezaei SJ, Adyani SM, Abazari M, Rahamooz Haghighi S, Abdollahi H, et al. Recent advances in targeting malaria with nanotechnology-based drug carriers. Pharm Dev Technol 2021; 26: 807-823.
29. Nosrati H, Salehiabar M, Bagheri Z, Rashidzadeh H, Davaran S, Danafar H. Preparation, characterization, and evaluation of amino acid modified magnetic nanoparticles: drug delivery and MRI contrast agent applications. Pharm Dev Technol 2018; 23: 1156-1167.
30. Islam R, Maeda H, Fang J. Factors affecting the dynamics and heterogeneity of the EPR effect: Pathophysiological and pathoanatomic features, drug formulations and physicochemical factors. Expert Opin Drug Deliv 2021; 19: 199-212.
31. Yoozbashi M, Rashidzadeh H, Kermanian M, Sadighian S, Hosseini M-J, Kaboli Z, et al. Magnetic nanostructured lipid carrier for dual triggered curcumin delivery: Preparation, characterization and toxicity evaluation on isolated rat liver mitochondria. J Biomater Appl 2022; 36: 1055-1063.
32. Rahmati M-A, Rashidzadeh H, Hosseini M-J, Sadighian S, Kermanian M. Self-assembled magnetic polymeric micelles for delivery of quercetin: Toxicity evaluation on isolated rat liver mitochondria. J Biomater Sci Polym ED 2022; 33: 279-298.
33. Gierlich P, Mata AI, Donohoe C, Brito RM, Senge MO, Gomes-da-Silva LC. Ligand-targeted delivery of photosensitizers for cancer treatment. Molecules 2020; 25: 5317-5370.
34. Khannanov A, Rossova A, Ulakhovich N, Evtugyn V, Valiullin L, Nabatov A, et al. Doxorubicin-Loaded Hybrid Micelles Based on Carboxyl-Terminated Hyperbranched Polyester Polyol. ACS Appl Polym Mater 2022; 4: 2553-2561.
35. Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine 2019; 86: 301-307.
36. Mousazadeh N, Gharbavi M, Rashidzadeh H, Nosrati H, Danafar H, Johari B. Anticancer evaluation of methotrexate and curcumin-coencapsulated niosomes against colorectal cancer cell lines. Nanomedicine 2022; 17: 201-217.
37. Galenkamp NS, Biesemans A, Maglia G. Directional conformer exchange in dihydrofolate reductase revealed by single-molecule nanopore recordings. Nat Chem 2020; 12: 481-488.
38. Aghajanzadeh M, Zamani M, Rashidzadeh H, Rostamizadeh K, Sharafi A, Danafar H. Amphiphilic Y shaped miktoarm star copolymer for anticancer hydrophobic and hydrophilic drugs codelivery: Synthesis, characterization, in vitro, and in vivo biocompatibility study. J Biomed Mater Res A 2018; 106: 2817-2826.
39. Kramer N, Walzl A, Unger C, Rosner M, Krupitza G, Hengstschläger M, et al. In vitro cell migration and invasion assays. Mutat Res 2013; 752:10-24.
40. Fattahi N, Ramazani A, Hamidi M, Parsa M, Rostamizadeh K, Rashidzadeh H. Enhancement of the brain delivery of methotrexate with administration of mid-chain ester prodrugs: In vitro and in vivo studies. Int J Pharm 2021; 600: 120479.
41. Nosrati H, Seidi F, Hosseinmirzaei A, Mousazadeh N, Mohammadi A, Ghaffarlou M, et al. Prodrug polymeric nanoconjugates encapsulating gold nanoparticles for enhanced x‐ray radiation therapy in breast cancer. Adv Healthc Mater 2022; 11: 2102321.
42. Zhang X, Yang Y, Liang X, Zeng X, Liu Z, Tao W, et al. Enhancing therapeutic effects of docetaxel-loaded dendritic copolymer nanoparticles by co-treatment with autophagy inhibitor on breast cancer. Theranostics 2014; 4: 1085-1095.
43. Nosrati H, Salehiabar M, Fridoni M, Abdollahifar M-A, Kheiri Manjili H, Davaran S, et al. New insight about biocompatibility and biodegradability of iron oxide magnetic nanoparticles: Stereological and  MRI monitor. Sci Rep 2019; 9: 1-10.
44. Jafari Iri Sofla F, Rahbarizadeh F, Ahmadvand D, Nomani A, Rahimi Jamnani F. Specific gene delivery mediated by poly (ethylene glycol)-grafted polyamidoamine dendrimer modified with a novel HER2-targeting nanobody. J Bioact Compat Polym 2015; 30: 129-144.
45. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007; 13: 223-230.
46. Wan J, Wu W, Zhang R, Liu S, Huang Y. Anti‑EGFR antibody conjugated silica nanoparticles as probes for lung cancer detection. Exp Ther Med 2017; 14: 3407-3412.
47. Zhang Q, Wu L, Liu S, Chen Q, Zeng L, Chen X. Moderating hypoxia and promoting immunogenic photodynamic therapy by HER-2 nanobody conjugate nanoparticles for ovarian cancer treatment. Nanotechnology 2021; 32: 425101.